title: Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era.
abstract: OBJECTIVE
  The second Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting was held on December 1, 2012, and included international multidisciplinary representatives of the 24 member groups. The aims were to review recent advances in molecular pathology of endometrial cancer, focusing on molecular-based therapy, and to identify key hypotheses and issues to be addressed through international collaborative clinical trials.
  
  
  METHODS
  Reviews and summaries of current knowledge were presented followed by parallel working group sessions for surgery, adjuvant and systemic therapy, and translational research. Plenary discussions were held to integrate translational and clinical issues, and a final discussion session to agree on key trial concepts.
  
  
  CONCLUSIONS
  Proposals to take forward on the following trials were agreed: (1) lymphadenectomy to direct adjuvant treatment in women with high-risk endometrial cancer, including a sentinel node substudy; (2) conservative therapy for low-risk endometrial cancers in morbidly obese women with high surgical risks and for fertility-sparing treatment in premenopausal patients; (3) adjuvant therapy for women with early-stage carcinosarcoma. A proposal was made that a GCIG Early Phase Consortium be developed to serve as an international platform for rapid assessment of biomarkers.
authors.affiliation: *Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands; †Institute of Cancer Sciences, University of Manchester, United Kingdom; ‡Division of Hematology and Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA; §Division of Gynaecology, European Institute of Oncology, Milan, Italy; ∥Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, TX; ¶Department of Clinical Oncology, Barts Health NHS Trust, London, United Kingdom; #Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; **Department of Gynaecology, Newcastle University and Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom; ††Department of Obstetrics and Gynecology, College of Medicine, Ohio State University, Columbus, OH; ‡‡Department of Gynaecologic Oncology, Royal Women's Hospital, and Melbourne University Dept of Obstetrics and Gynaecology, Australia; §§Department of Obstetrics and Gynecology, Haukeland University Hospital; and Department of Clinical Medicine, University of Bergen, Norway; and ∥∥Department of Radiation Oncology, Sunnybrook Cancer Center, Toronto, Canada.
authors.forename: Carien L
authors.initials: CL
authors.lastname: Creutzberg
authors.forename: Henry C
authors.initials: HC
authors.lastname: Kitchener
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Birrer
authors.forename: Fabio
authors.initials: F
authors.lastname: Landoni
authors.forename: Karen H
authors.initials: KH
authors.lastname: Lu
authors.forename: Melanie
authors.initials: M
authors.lastname: Powell
authors.forename: Carol
authors.initials: C
authors.lastname: Aghajanian
authors.forename: Richard
authors.initials: R
authors.lastname: Edmondson
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Goodfellow
authors.forename: Michael
authors.initials: M
authors.lastname: Quinn
authors.forename: Helga B
authors.initials: HB
authors.lastname: Salvesen
authors.forename: Gillian
authors.initials: G
authors.lastname: Thomas
mesh_terms: D002986:Clinical Trials as Topic; D016889:Endometrial Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D057170:Translational Research, Biomedical